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(http://creativecommoWe assessed whether short-latency afferent inhibition (SAI), a transcranial magnetic stimulation
paradigm that assesses cholinergic circuits of the brain, could become such a biomarker.
Methods: Nineteen patients with AD underwent four SAI testing sessions. The timing of their usual
donepezil dose was altered to create different cholinergic states for each session. This was compared
to the SAI results from 20 healthy subjects.
Results: SAI was not able to distinguish the different cholinergic states assessed in our study. There
appeared to be a diurnal variation in cholinergic function in the control group, which was not present
in the AD cohort.
Discussion: SAI does not appear to have a role in diagnosis and assessment of AD patients. The loss
of diurnal variation, however, warrants further investigation as it may provide further biochemical
insights about AD.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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Alzheimer’s disease (AD) is the most common neurode-
generative disorder affecting cognition, usually beginning
with memory impairment and executive dysfunction [1].
Biochemically, it is characterized by a cholinergic deficit
in the brain [2]. Increasing acetylcholine levels using a
cholinesterase inhibitor (ChEI) such as donepezil can pro-
duce a modest symptomatic benefit in patients with AD
[1]. Cholinergic deficit parallels worsening of cognitive def-
icits despite treatment with a ChEI [3]..
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ns.org/licenses/by/4.0/).Currently available biomarkers of AD are nonspecific,
invasive, and/or expensive. There is a need to develop reli-
able, noninvasive, safe, and cheap biomarkers for AD that
can assess disease progression over time. Such biomarkers
will be invaluable in confirming the diagnosis and could
act as a quantitative and/or objective marker of potential
therapeutic benefit in clinical trials.
Transcranial magnetic stimulation (TMS) is a noninva-
sive, relatively cheap neurophysiological technique that
assesses the excitability of the motor cortex. A specific
paradigm—short-latency afferent inhibition (SAI), which
couples TMS with a conditioning electric stimulus on
the peripheral nerve—has been designed to measure the
excitability of cholinergic circuits within human cerebral
motor cortex [4,5]. This results in a reduction in
amplitude of motor evoked potentials (MEPs) obtainedeimer’s Association. This is an open access article under the CC BY license
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intravenous scopolamine, suggesting that it is at least
partly mediated by cortical cholinergic activity [5]. In a
small study, AD patients had reduced SAI compared to
control subjects reflecting their cholinergic dysfunction
[6]. In a subgroup of six AD patients in the same study,
SAI increased after a single dose of rivastigmine, a
ChEI [6]. This study aimed to assess whether SAI can
be used as a biomarker of AD pathology and response
to treatment with a ChEI.
2. Materials and methods
2.1. Participants
Nineteen AD patients meeting the consensus criteria
for typical mild-to-moderate AD [7] treated with donepe-Table 1
Demographic and neurophysiological profiles of the participants
Control AD
Gender (M:F) 9:11 9:10
Age (years 6 SD) 66.3 6 7.0 71.0 6 8.1
Handedness (R:L) 19:1 19:0
MMSE (/30 6 SD) 29.8 6 0.5 23.4 6 3.3
MMSE , 24 0 11
Symptom duration (years 6 SD) N/A 4.0 6 2.0
Range of symptoms (years 6 SD) N/A 2–8
Donepezil taken (night:day) N/A 12:8
Donepezil dose (10 mg:5 mg) N/A 18:1*
Donepezil treatment duration
(years 6 SD)
N/A 1.7 6 1.1
Interval between 2 visits (days 6 SD) 13.7 6 1.0 14.4 6 2.3
Sensory threshold (mA 6 SE)
Morning 2.60 6 0.96 2.80 6 1.08
Afternoon 2.55 6 0.78 2.88 6 0.91
SEP stimulation intensity (mA 6 SE)
Morning 7.79 6 2.89 8.36 6 3.30
Afternoon 7.64 6 2.45 8.78 6 2.74
N20 latency (ms 6 SE)
Morning 20.43 6 1.24 20.26 6 1.42
Afternoon 20.44 6 1.43 20.11 6 1.45
N20-P25 amplitude (mV 6 SE)
Morning 6.19 6 3.28 6.37 6 3.53
Afternoon 6.45 6 3.32 6.54 6 3.88
Resting motor threshold (%MSO 6 SE)
Morning 47.65 6 8.17 49.24 6 12.22
Afternoon 47.60 6 9.84 49.95 6 12.70
1 mV motor threshold (%MSO 6 SE)
Morning 64.41 6 14.44 71.74 6 17.89
Afternoon 62.49 6 13.74 72.34 6 21.09
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; SE,
standard error; M, male; F, female; R, right; L, left; MMSE, Folstein
Mini–Mental Status Examination; N/A, not applicable; SEP, sensory evoked
potential; MSO, maximum stimulator output.
NOTE. Resting motor threshold and 1-mVmotor threshold are measured
as a percentage of the maximum stimulator output.
*One patient on 5 mg did not tolerate titration to 10 mg and was stepped
down to 5 mg several months before enrollment in this study.zil once daily and 20 healthy subjects (HS) participated
in the study. Their demographics and clinical character-
istics are summarized in Table 1. This study has
been approved by the appropriate local and national
research ethics committees, and all participants gave
informed consent in accordance with the Declaration of
Helsinki.
2.2. Experimental procedures
SAI was tested four times over two separate visits in all
participants. There were two sessions per visit, 4 hours
apart (“morning” and “afternoon” sessions). The AD
group was asked to delay their daily dose of donepezil
preceding the visit until immediately after the completion
of the morning TMS session, for an interval of at least
24 hours between donepezil ingestion and the morning
TMS session. This timing was based on the pharmacoki-
netic properties of donepezil to create a relatively
deficient cholinergic state for the morning session,
compared to the afternoon session occurring 4 hours later,
when the serum level of donepezil is expected to be at its
peak [8,9].
2.3. Resting motor threshold and SAI
Resting motor threshold was defined as the lowest
TMS intensity applied over the left primary motor cortex
able to evoke an MEP of at least 50 mV in 5 of 10 consec-
utive trials during rest in the right first dorsal interosseous
muscle. SAI was performed using the method previously
described by Tokimura et al. [4]. Briefly, SAI was ob-
tained by coupling a TMS pulse applied over primary mo-
tor cortex, at an intensity able to elicit a MEP of around
1 mV amplitude from the right first dorsal interosseous
(1 mV-int), with an electric stimulus of 200 ms duration
and a somatosensory stimulation intensity (SST) of
300% of the somatosensory threshold over the right me-
dian nerve. The interstimulus interval (ISI) between elec-
tric and magnetic pulse was adjusted based on individual
latency of the N20 component of somatosensory evoked
potentials recorded over the left hemisphere according
to current guidelines [10], using the same SST of SAI.
Fifteen trials for single, control TMS pulse and for each
ISI (N20 12, 14, 16 and 18 ms) were collected in a ran-
domized order. SAI was then calculated as the ratio be-
tween the averages of conditioned and control MEP at
each ISI.
2.4. Statistical analysis
Age and neurophysiological variables (SST, somato-
sensory evoked potential N20 latency, somatosensory
evoked potential N20-P25 amplitude, resting motor
threshold, and 1 mV-int) were compared between AD
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analyses of variance (ANOVAs) with “group” and “ses-
sion” as factors of analysis. A two-way ANOVA with
“group” and “session” as factors of analysis was used
to compare the test MEP amplitudes. A mixed three-
way ANOVA with “group,” “session,” and “ISI” as fac-
tors of analysis was performed on SAI ratios to investi-
gate possible SAI changes between HS and AD
patients in different sessions and ISI. Several other
three-way repeated-measures ANOVAs with “session,”
“muscle,” and “ISI” as factors of analysis were per-
formed on SAI ratios in the AD group adding disease
severity and time of donepezil intake as covariates. Pear-
son’s correlation coefficient was used to investigate
possible correlations between SAI ratios (for each ISI
and averaged across ISIs) and clinical variables (disease
duration and Mini–Mental Status Examination values) in
AD patients. To assess the reproducibility of SAI, Pear-
son’s correlation coefficient was used to investigate cor-
relation between SAI values, averaged across the four
ISI, in the four different sessions in HS and AD
patients separately. Normality of distribution was as-
sessed with the Shapiro-Wilks’ test, whereas homogene-
ity of variance was assessed by Levene’s test.
Greenhouse-Geisser correction was used where appli-
cable in case of violation of sphericity. P values , .05
were considered significant. Bonferroni correction was
used for post hoc comparisons.Fig. 1. Short-latency afferent inhibition associated with each interstimulus
interval state. The averages of the transcranial magnetic stimulation (TMS)
evoked motor potentials in mV for each state expressed as a percentage of
the control pulse for each experimental group across both days. The error
whiskers represent the standard error. Each interstimulus interval (ISI)
was derived from each participant’s individual N20 via sensory evoked po-
tential. ISI 15 control state with TMS only; ISI 25 TMS after the periph-
eral nerve stimulation at N20 1 2 ms; ISI 3 5 TMS after the peripheral
nerve stimulation at N20 1 4 ms; ISI 4 5 TMS after the peripheral nerve
stimulation at N20 1 6 ms; ISI 5 5 TMS after the peripheral nerve stimu-
lation at N201 8 ms. Abbreviations: AD, Alzheimer’s disease; SAI, short-
latency afferent inhibition.3. Results
All variables were normally distributed (P values of the
Shapiro-Wilks’ test were always . .05), and Levene’s test
did not disclose violation of homogeneity of variance. The
multiple two-way mixed ANOVAs did not show any main
effects or interactions of factors “group” and “session”
when comparing SST, N20 latency, N20-P25 amplitude,
and resting motor threshold (Table 1). 1 mV-int was larger
in AD patients than in HS, although the main effect of the
“group” factor of the related ANOVA did not reach statis-
tical significance (F1,35 5 3.085, P 5 .088) and there were
no factor interactions. The two-way mixed ANOVA with
factors “group” and “session” done to compare test
MEPs did not disclose significant main effects or interac-
tions. The three-way mixed ANOVA with “group,” “ses-
sion,” and “ISI” factors on SAI ratio only disclosed a
significant main effect of “ISI” (F3,102 5 71.530,
P , .001); no other main effects or factor interactions
were observed. Post hoc comparisons showed that shorter
ISI led to significantly greater inhibition compared to
longer ones. Time of intake and dose of donepezil did
not show any effect as covariates. No correlation was found
in AD patients between Mini–Mental Status Examination
and SAI measured for each ISI and averaged across allISIs. Pearson’s correlation coefficient showed no correla-
tion in the SAI among the four different sessions in AD pa-
tients, whereas a significant correlation was found in
the control group between the morning and the afternoon
sessions.4. Discussion
In our study, SAI was not able to distinguish the cholin-
ergic deficit state in AD patients compared with HS
(Fig. 1). Furthermore, SAI did not detect change in the
cholinergic state before and after donepezil administration
in AD patients. Interestingly, correlation in SAI among the
four sessions was significant in HS, while it was not in AD
patients. This indicates a greater variability of cortical
cholinergic transmission in the AD group and raises a possi-
bility that there is a diurnal variability in the cholinergic state
in HS, which is lost in AD, either as a result of the underlying
neurodegenerative process or because of the treatment
boosting acetylcholine labels.
Our results are different from a previous report that
found significantly reduced SAI in AD patients compared
to HS [6]. The major difference in the study subjects is
that AD patients studied by Di Lazzaro et al. [6] were
na€ıve to treatment with ChEI, while our patients had
been on donepezil long term (average of 20.8 months)
before undergoing SAI 24–36 hours after the last dose
of ChEI. A modicum of cholinesterase inhibition still pre-
sent in our subjects may be sufficient to restore SAI to
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at least pharmacologically, the ceiling effect of ChEI
may be attained at lower doses of ChEI. Another possible
explanation, previously reported in rats [11], is that
chronic donepezil administration induces neuroplastic
changes in the brain to adapt to the damages acquired
from the neurodegenerative disorders, although it is not
known whether such changes occur in humans at this
stage.
The results of our study indicate that SAI is not suffi-
ciently sensitive to differentiate between the deficient
and normal cholinergic states in AD patients on long-
term therapy with ChEI and HS or detect a change in
the cholinergic state before and after the administration
of the daily dose of donepezil in these AD patients. The
results suggest that SAI is unlikely to be a useful
biomarker that can reliably detect changes in cholinergic
function to distinguish ChEI responders from nonre-
sponders or as an effect of treatment with other symptom-
atic or disease-modifying treatment for AD above and
beyond ChEI. However, the loss of correlation between
SAI in the four sessions, which was present among HS,
warrants further investigation. If these intriguing results
are replicated, then this may indicate the loss of normal
diurnal variability of cholinergic function in AD patients,
compared to unaffected individuals, potentially providing
new insights into pathological biochemical process under-
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Helsinki.RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional sources (e.g., PubMed). There
are no reports assessing the response to treatment
with donepezil in Alzheimer’s disease (AD) with
transcranial magnetic stimulation (TMS); the exist-
ing literature focuses on the potential role of TMS
in AD diagnosis. The relevant articles have been
cited appropriately in the text.
2. Interpretation: Our finding suggests that TMS is not
sufficiently sensitive to distinguish between control
participants and AD patients on chronic donepezil
therapy.
3. Future directions: Despite the negative results, our
study also suggests two new, intriguing avenues to
explore: the existence of a diurnal variation in
acetylcholine activity in healthy controls, which
is lost in AD; and whether neuroplastic changes,
detectable with TMS, occur in AD in response to
chronic donepezil administration. This could pro-
vide additional insights into biochemistry and path-
ophysiology of AD.References
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